Our results are supported by preclinical evidence that shows that the administration of KMO inhibitors counteracted the effects of neuroinflammation in various neurodegenerative diseases (Campbell et al., 2014; Wilson et al., 2014). The gene discussed is KMO; the disease is neurodegenerative disease.